Vaccination of mice with recombinant bacille Calmette-Guérin harboring Rv1357c protects similarly to native BCG [Short communication]

Despite the availability of a Mycobacterium bovis bacille Calmette Guérin (BCG) vaccine, tuberculosis (TB) remains a global public health problem. In this study, we introduced the c-di-GMP phosphodiesterase gene Rv1357c, implicated in regulating mycobacterial replication within macrophages, into BCG...

Full description

Saved in:
Bibliographic Details
Published inThe international journal of tuberculosis and lung disease Vol. 16; no. 6; pp. 774 - 776
Main Authors Flores-Valdez, M. A., de Jesús Aceves-Sánchez, M., Montero-Pérez, S. A., Sánchez-López, A. D., Gutiérrez-Pabello, J. A., Hernández-Pando, R.
Format Journal Article
LanguageEnglish
Published Paris, France International Union Against Tuberculosis and Lung Disease 01.06.2012
International Union against Tuberculosis and Lung Disease
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite the availability of a Mycobacterium bovis bacille Calmette Guérin (BCG) vaccine, tuberculosis (TB) remains a global public health problem. In this study, we introduced the c-di-GMP phosphodiesterase gene Rv1357c, implicated in regulating mycobacterial replication within macrophages, into BCG Pasteur, and tested the resulting strain for its capacity to serve as a vaccine against TB in a murine model. Modified BCG was more phagocytosed than its parental strain, but halted bacterial replication, and protected against M. tuberculosis challenge similarly to unmodified BCG.
Bibliography:1027-3719(20120601)16:6L.774;1-
(R) Medicine - General
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1027-3719
1815-7920
DOI:10.5588/ijtld.11.0735